**Supplementary Table 1.** Adverse events during treatment with ramucirumab in patients with advanced hepatocellular carcinoma.

|  |  |
| --- | --- |
| **Events** | **All patients (n= 37)** |
| **Any** | **Grade ≥ 3** |
| Hypertension | 20 (54.0%) | 2 (5.4%) |
| Hypoalbuminemia | 15 (40.5%) | 0 |
| Proteinuria | 13 (35.1%) | 1 (2.7%) |
| Increased aspartate aminotransferase  | 12 (32.4%) | 0 |
| Edema | 11 (29.7%) | 0 |
| Decreased platelet count  | 9 (24.3%) | 0 |
| Anorexia | 8 (21.6%) | 2 (5.4%) |
| Fatigue | 8 (21.6%) | 2 (5.4%) |
| Increased alanine aminotransferase  | 7 (18.9%) | 0 |
| Bleeding | 5 (13.5%) | 1 (2.7%) |
| Elevated ammonia | 4 (10.8%) | 0 |
| Diarrhea | 3 (8.1%) | 0 |
| Increased serum amylase  | 2 (5.4%) | 0 |
| Anemia | 2 (5.4%) | 0 |
| Blood bilirubin | 2 (5.4%) | 0 |
| Fever | 2 (5.4%) | 0 |
| Infusion reaction | 1 (2.7%) | 0 |
| Weight loss | 1 (2.7%) | 0 |
| Hyperuricemia | 1 (2.7%) | 1 (2.7%) |

**Supplementary Table 2.** Best response, objective response rate, and disease control rate during ramucirumab treatment.

|  |  |
| --- | --- |
|  | **All patients (n= 37)** |
| **RECIST**Complete responsePartial responseStable diseaseProgressive diseaseObjective response rateDisease control rate | 01 (2.7%)18 (48.6%)14 (37.8%)1 (2.7%)19 (51.4%) |
| **mRECIST**Complete responsePartial responseStable diseaseProgressive diseaseObjective response rateDisease control rate | 07 (19.0%)11 (29.7%)13 (35.1%)7 (19.0%)17 (45.9%) |

RECIST, Response Evaluation Criteria in Solid Tumors; mRECIST, modified RECIST